🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,760 results for “Pharm” Clear

  1. SCD-044 Tablets 0.3mg, SCD-044 Tablets 0.6mg, SCD-044 Tablets 1.0mg, SCD-044 Tablets 0.1mg, placebo to match SCD-044 tablets

    Lacuna Pharma Pty Ltd

    moderate to severe plaque psoriasis

    phase 2 small molecule active

    1 trial

  2. SDX-101 (R-Etodolac)

    Teva Pharma GmbH

    Multiple Myeloma

    phase 2 small molecule terminated

    1 trial

  3. SDX-105

    Teva Pharma GmbH

    Non-Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial

  4. SELINEXOR

    Karyopharm Therapeutics Inc

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  5. SHJ002/Vehicle

    Biotech Pharmaceutical Co.,

    Dry Eye Disease

    phase 2 small molecule completed

    1 trial

  6. SHP626

    Mirum Pharmaceuticals International B.V.

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule completed

    3 trials

  7. SI-B001

    Sichuan Baili Pharmaceutical Co.,

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  8. SIROLIMUS

    Pari Pharma GmbH

    Adult patients (men and women) (≥ 18 years of age) with cutaneous sarcoidosis involving the face

    phase 2 small molecule active

    1 trial

  9. SIROLIMUS, BEKEMV 300 mg concentrate for solution for infusion, SIROLIMUS, PREDNISONE, METHYLPREDNISOLONE SODIUM SUCCINATE, PARACETAMOL, Epysqli 300 mg concentrate for solution for infusion, PREDNISONE, DIPHENHYDRAMINE HYDROCHLORIDE, SIROLIMUS, PREDNISONE, RITUXIMAB, RITUXIMAB, ECULIZUMAB, BEKEMV 300 mg concentrate for solution for infusion, AAV9.LAMP2B, DIPHENHYDRAMINE HYDROCHLORIDE, PARACETAMOL, METHYLPREDNISOLONE SODIUM SUCCINATE, PREDNISONE, SIROLIMUS, BEKEMV 300 mg concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Danon Disease

    phase 2 small molecule active

    1 trial

  10. SIROLIMUS, SIROLIMUS

    Lacuna Pharma Pty Ltd

    Subjects diagnosed with port wine stains

    phase 2 small molecule active

    1 trial

  11. SNDX-5613

    Syndax Pharmaceuticals

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  12. SNDX-6352

    Syndax Pharmaceuticals

    Coronavirus

    phase 2 small molecule terminated

    1 trial

  13. SODIUM CHLORIDE

    Lacuna Pharma Pty Ltd

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  14. SODIUM CHLORIDE , DII235

    Novartis Pharmaceuticals

    Cardiovascular risk reduction in participants with elevated Lp(a)

    phase 2 small molecule active

    1 trial

  15. SODIUM CHLORIDE SOLUTION 0.9%

    Lacuna Pharma Pty Ltd

    Acute Ischemic Stroke

    phase 2 small molecule active

    1 trial

  16. SODIUM CHLORIDE, MYDRIASERT, insert ophtalmique, 0.34 % tropicamide/ 2.5 % phenylephrine hydrochloride

    Lacuna Pharma Pty Ltd

    to obtain pre-operative mydriasis or for diagnostic purposes

    phase 2 small molecule active

    1 trial

  17. SPGL008

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    NMIBC

    phase 2 mab active

    1 trial

  18. SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

    Lacuna Pharma Pty Ltd

    Hypercortisolism related to benign adrenal tumour

    phase 2 other active

    1 trial

  19. SPI-62_DF2

    Lacuna Pharma Pty Ltd

    Cushing's Syndrome

    phase 2 small molecule active

    1 trial

  20. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Disorder With Hyperactivity

    phase 2 small molecule completed

    1 trial

  21. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Impulsive Aggression Comorbid With ADHD

    phase 2 small molecule completed

    1 trial

  22. SPN-817

    SUPERNUS PHARMACEUTICALS, INC.

    Focal Onset Seizures

    phase 2 small molecule active

    2 trials

  23. SPN-817

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsy

    phase 2 small molecule active

    1 trial

  24. SPN-821 2400 mg

    SUPERNUS PHARMACEUTICALS, INC.

    Major Depressive Disorder (MDD)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources